Savold Jordan, Cole Michele, Thorpe Roland J
Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA.
Global Market Access, Neuroscience Therapeutic Area Johnson & Johnson Raritan New Jersey USA.
Alzheimers Dement (N Y). 2023 Jul 4;9(3):e12402. doi: 10.1002/trc2.12402. eCollection 2023 Jul-Sep.
Black Americans are disproportionately burdened by Alzheimer's disease (AD) relative to other racial groups in the United States and continue to be underrepresented in AD clinical trials. This review explores the primary barriers for participation in clinical trials among Black Americans and provides literature-based recommendations to improve the inclusion of Black Americans in AD clinical trials.
We searched electronic databases and gray literature for articles published in the United States through January 1, 2023, ultimately identifying 26 key articles for inclusion.
Barriers to participation in clinical trials for Black Americans are rooted in social determinants of health, including access to quality education and information, access to health care, economic stability, built environment, and community context. Best practices to improve the inclusion of Black Americans in clinical trials require pharmaceutical companies to adopt a multifaceted approach, investing in innovative strategies for site selection, development of local partnerships, outreach, and education.
While multisectoral action must occur to effectively address the disproportionate burden of AD on Black Americans, the pharmaceutical industry has an important part to play in this space due to their central role in product development and clinical trials.
与美国其他种族群体相比，非裔美国人受阿尔茨海默病（AD）的影响尤为严重，且在AD临床试验中的代表性仍然不足。本综述探讨了非裔美国人参与临床试验的主要障碍，并基于文献提出建议，以提高非裔美国人在AD临床试验中的纳入率。
我们检索了电子数据库和灰色文献，查找截至2023年1月1日在美国发表的文章，最终确定了26篇关键文章纳入综述。
非裔美国人参与临床试验的障碍源于健康的社会决定因素，包括获得优质教育和信息的机会、获得医疗保健的机会、经济稳定性、建成环境和社区环境。提高非裔美国人在临床试验中纳入率的最佳做法要求制药公司采取多方面的方法，投资于创新的选址策略、发展当地合作伙伴关系、开展宣传和教育。
虽然必须采取多部门行动来有效解决AD对非裔美国人造成的不成比例负担，但制药行业在这一领域可发挥重要作用，因为它们在产品开发和临床试验中起着核心作用。
